Monoclonal antibody-mediated neutralization of SARS-CoV-2 in an IRF9-deficient child.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 34702736.
- Also identified by DOI 10.1073/pnas.2114390118 and PMC identifier 8609338.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We describe an unvaccinated child at risk for life-threatening COVID-19 due to an inherited deficiency of IRF9, which governs ISGF-3-dependent responses to type I and III interferons (IFN). She was admitted, with a high nasal SARS-CoV-2 load on day 1 of upper respiratory tract infection. She was viremic on day 2 and received casirivimab and imdevimab. Her clinical manifestations and viremia disappeared on days 3 and 4, respectively. Circulating SARS-CoV-2 virus induced the expression of IFN-stimulated genes in leukocytes on day 1, whereas the secretion of blood type I IFNs, which peaked on day 4, did not. Antibody-mediated SARS-CoV-2 neutralization is, therefore, sufficient to overcome a deficiency of antiviral IFNs.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- COVID-19
- Interferon-Stimulated Gene Factor 3, gamma Subunit
- SARS-CoV-2